PRESS RELEASE published on 08/25/2025 at 07:00, 11 months 18 days ago OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting OSE Immunotherapeutics announces proposed governance evolution and reaffirms strategic priorities ahead of Annual General Meeting. Company focuses on Tedopi® and Lusvertikimab to unlock full potential Strategic Priorities Governance Evolution OSE Immunotherapeutics Lusvertikimab Tedopi
BRIEF published on 08/20/2025 at 18:05, 11 months 22 days ago OSE Immunotherapeutics Appoints Thomas Gidoin as CFO Chief Financial Officer Strategic Planning Biotech Financing OSE Immunotherapeutics Thomas Gidoin
BRIEF published on 08/20/2025 at 18:05, 11 months 22 days ago OSE Immunotherapeutics nomme Thomas Gidoin au poste de directeur financier Directeur Financier Planification Stratégique OSE Immunotherapeutics Financement Des Biotechnologies Thomas Gidoin
PRESS RELEASE published on 08/20/2025 at 18:00, 11 months 22 days ago OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer OSE Immunotherapeutics appoints Thomas Gidoin as Chief Financial Officer, bringing deep expertise in capital markets and financial strategy to the company. Gidoin succeeds Anne-Laure Autret-Cornet Chief Financial Officer Capital Markets Financial Strategy OSE Immunotherapeutics Thomas Gidoin
PRESS RELEASE published on 08/20/2025 at 18:00, 11 months 22 days ago OSE Immunotherapeutics nomme Thomas Gidoin au poste de Directeur Financier Nomination de Thomas Gidoin comme nouveau Directeur Financier chez OSE Immunotherapeutics. Il apporte 15 ans d'expertise internationale en finance et gouvernance Biotechnologie Finance Directeur Financier OSE Immunotherapeutics Thomas Gidoin
BRIEF published on 07/02/2025 at 08:05, 1 year 1 month ago OSE Immunotherapeutics Updates on Legal Proceedings Transparency Shareholder Meeting Legal Proceedings OSE Immunotherapeutics Nantes Commercial Court
BRIEF published on 07/02/2025 at 08:05, 1 year 1 month ago Mises à jour d'OSE Immunotherapeutics sur les procédures judiciaires Transparence Assemblée Des Actionnaires OSE Immunotherapeutics Procédures Judiciaires Tribunal De Commerce De Nantes
PRESS RELEASE published on 07/02/2025 at 08:00, 1 year 1 month ago OSE Immunotherapeutics met à jour l’information sur les procédures en cours OSE Immunotherapeutics provides an update on ongoing legal proceedings regarding shareholders' motions, confirms plans for annual shareholders' meeting on September 30, 2025 Shareholders Biotech Annual Meeting Legal Proceedings OSE Immunotherapeutics
PRESS RELEASE published on 07/02/2025 at 08:00, 1 year 1 month ago OSE Immunotherapeutics met à jour l’information sur les procédures en cours Mise à jour des procédures en cours par OSE Immunotherapeutics concernant une action en justice et la tenue de leur assemblée générale annuelle. Vision prospective de l'entreprise Biotechnologie Procédures En Cours Déclarations Prospectives Assemblée Générale Annuelle OSE Immunotherapeutics
BRIEF published on 06/20/2025 at 19:35, 1 year 1 month ago OSE Immunotherapeutics sécurise son Assemblée Générale Actionnaires Assemblée Générale Transparence OSE Immunotherapeutics Procédures Judiciaires
Published on 08/12/2026 at 15:42, 15 minutes ago Critical Elements 10,000-Meter Summer Drill Program at Rose West Resumes with Positive Results
Published on 08/12/2026 at 15:42, 15 minutes ago Critical Elements redémarre son programme de forage estival de 10 000 mètres à Rose Ouest avec des résultats positifs
Published on 08/12/2026 at 15:00, 57 minutes ago Karbon-X and Core Energy Sign Letter of Intent to Explore Commercial EV Charging Infrastructure in South America
Published on 08/12/2026 at 14:45, 1 hour 12 minutes ago Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Published on 08/11/2026 at 17:45, 22 hours 12 minutes ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 22 hours 17 minutes ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 1 day 21 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 1 day 21 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
